Vitamin D supplements reliably lift blood levels of the sunshine vitamin in children and adolescents who carry excess weight, but they do little to improve the metabolic and cardiovascular problems that often accompany childhood obesity. That is the central conclusion of a new systematic review and meta-analysis published in the International Journal of Obesity, which pooled evidence from randomized controlled trials testing cholecalciferol supplementation in young people with overweight or obesity. The findings confirm what many pediatric endocrinologists have long suspected: correcting low vitamin D status is achievable and safe, yet it is not, by itself, a shortcut to better metabolic health.

The research team, led by Alia Iftikhar of King Edward Medical University in Lahore, Pakistan, set out to answer two related questions. First, does vitamin D supplementation actually raise serum levels of 25-hydroxyvitamin D, the standard laboratory measure of vitamin D status, in children whose body fat stores tend to sequester the nutrient? Second, if levels do rise, does that translate into measurable improvements in body mass index, blood lipids, insulin sensitivity, or markers of cardiovascular risk? To find out, the researchers searched PubMed, Embase, and Google Scholar using a structured search string that combined terms for vitamin D, obesity and overweight, randomized trials, and pediatric populations.

The screening process identified 24 studies that met the inclusion criteria, spanning trials of varying formulations, dosages, and durations. Of these, 11 randomized controlled trials provided data suitable for quantitative meta-analysis. The team assessed the methodological quality of the included studies using the Cochrane Risk of Bias tool, known as ROB-2, which evaluates potential sources of bias in randomized trial design, conduct, and reporting. Follow-up periods across the trials ranged from as short as eight weeks to as long as twelve months, with assessments conducted at intervals including three, six, and twelve months.

The primary outcome, serum vitamin D levels, showed a clear and statistically significant benefit from supplementation. In the meta-analysis, children assigned to vitamin D supplementation had serum 25-hydroxyvitamin D concentrations that exceeded those of placebo recipients by a standardized mean difference of 3.12 nanograms per milliliter, with a 95 percent confidence interval of 1.72 to 4.52. In practical terms, this means that supplementing children with overweight or obesity does correct the relative deficiency that their larger fat stores tend to create, even if the magnitude of the increase varies from trial to trial.

Why would children with obesity be prone to low vitamin D in the first place? The answer lies in the chemistry of the molecule itself. Vitamin D, specifically 25-hydroxycholecalciferol, is lipophilic, meaning it dissolves readily in fat rather than water. In people with larger adipose depots, a greater fraction of circulating vitamin D partitions into fat tissue, effectively diluting the amount available in the bloodstream. Researchers have described this as volumetric dilution rather than simple sequestration, and studies dating back more than a decade have documented the inverse relationship between body fat indexes and vitamin D status in adolescents. The new analysis confirms that supplementation can overcome this dilution effect, at least partially.

The safety picture was reassuring. Across the included trials, no adverse events were reported following supplementation, an important finding given that some of the studies tested relatively high doses of the vitamin. Vitamin D toxicity, which can cause hypercalcemia and kidney problems, is a legitimate concern at very high intakes, but the pooled evidence suggests that the regimens used in these pediatric trials were well tolerated. For clinicians weighing whether to treat documented deficiency in young patients with obesity, the analysis offers support for the safety of doing so.

The secondary outcomes tell a more sobering story. The review observed some favorable signals, including decreases in body mass index, serum triglycerides, and inflammatory markers among supplemented children. However, when the researchers examined the broader picture of metabolism and cardiovascular health, the effects did not reach statistical significance. Insulin sensitivity, a key determinant of future type 2 diabetes risk, did not improve consistently, and cardiovascular risk markers overall remained essentially unchanged. In other words, raising blood vitamin D levels did not translate into the cardiometabolic benefits that observational studies had hinted at.

This disconnect between vitamin D status and metabolic outcomes is consistent with a growing body of evidence across age groups. Observational studies have repeatedly linked low vitamin D levels with obesity, insulin resistance, and cardiovascular disease, but such associations are notoriously vulnerable to confounding, since obesity itself drives both low vitamin D and poor metabolic health. Randomized trials, which isolate the effect of supplementation, have generally been less enthusiastic. Previous systematic reviews of vitamin D supplementation in children and adolescents have similarly found little consistent effect on cardiometabolic outcomes, and trials in obese adolescents have reported that even large doses sometimes fail to alter cardiovascular risk factors or beta-cell function.

The authors of the new analysis are careful about what their findings do and do not support. Vitamin D supplementation in children with overweight or obesity corrects deficiency and significantly raises serum levels without adverse events, they conclude, but new trials should be conducted to identify effective therapies that genuinely enhance metabolic and cardiovascular outcomes in this population. That framing matters, because it redirects attention away from vitamin D as a standalone intervention and toward the harder question of what actually improves insulin sensitivity, lipid profiles, and vascular health in young people with excess weight.

For families and clinicians, the practical takeaways are relatively straightforward. Children and adolescents with obesity are at elevated risk of vitamin D deficiency, which can compromise bone mineralization during a critical window of skeletal development, and supplementation is a safe and effective way to restore adequate blood levels. But parents hoping that a daily capsule will melt away metabolic risk are likely to be disappointed. The evidence now suggests that vitamin D is a necessary nutrient whose correction supports bone health, while the deeper drivers of cardiometabolic disease in pediatric obesity, including diet quality, physical activity, and sustained weight management, require interventions of a different kind. The 24 studies synthesized in this review, drawn from populations as diverse as South Asian, African American, Hispanic, Sri Lankan, and European children, collectively close one chapter on vitamin D in pediatric obesity and open another: the search for therapies that move the needle on the outcomes that matter most.

Subject of Research: Effects of vitamin D supplementation on serum vitamin D levels and cardiometabolic health outcomes in children and adolescents with overweight or obesity

Article Title: Effect of vitamin D supplementation on serum vitamin D levels and health outcomes in pediatric population with obesity/overweight: a systematic review and meta-analysis

Article References: Effect of vitamin D supplementation on serum vitamin D levels and health outcomes in pediatric population with obesity/overweight: a systematic review and meta-analysis. (n.d.). https://doi.org/10.1038/s41366-026-02231-y

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02231-y

Keywords: vitamin D, pediatric obesity, meta-analysis, systematic review, cholecalciferol, insulin sensitivity, cardiovascular risk, BMI, 25-hydroxyvitamin D, children, adolescents, supplementation